Atara Biotherapeutics, Inc.
ATRA
$15.63
$1.6511.80%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 112.53% | 219.71% | 79.00% | 68.61% | 73.21% |
| Total Depreciation and Amortization | -82.26% | 29.04% | -8.71% | 1.74% | 10.74% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -72.94% | 13.52% | -40.88% | -33.67% | -34.71% |
| Change in Net Operating Assets | -277.51% | -599.85% | -207.89% | 232.76% | -409.23% |
| Cash from Operations | 31.25% | 4.98% | 51.45% | 92.23% | 79.84% |
| Capital Expenditure | -- | -- | -104.55% | 100.00% | 94.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -175.00% | 15.86% | -65.30% | -123.57% | -85.54% |
| Cash from Investing | -170.46% | 16.86% | -66.05% | -123.66% | -85.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | -10.13% | -9.30% | 5.29% | -9.91% |
| Issuance of Common Stock | -98.92% | -- | -- | -- | -86.66% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 8,416.85% | -- | -- | -- | -1,315.38% |
| Cash from Financing | 4,823.46% | -101.04% | -121.69% | 17,308.17% | -168.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 177.29% | -221.01% | 45.00% | -19.87% | -32.71% |